Oncology

The associate professor at Fred Hutch Cancer Center discussed new data on the CD20-targeting CAR he presented at ASH 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Clinical holds have been placed on BCMA-targeted CT053, GPRC5D-targeted CT071, and Claudin18.2-targeted CT041.

The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed possible research to move forward with CD19 T-APCs for patients with B-ALL.

The professor of hematology at University of Lille and chair of LYSA also discussed what the group will be focusing on in 2024.

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed the need for research into how CAR T-cells act differently between sexes.

Review top news and interview highlights from the week ending December 15, 2023.

The hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.

The chief medical officer of Orca Bio discussed some trends he was excited about at ASH’s 2023 conference.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief hematology/oncology fellow at University of Chicago discussed new data from the ROCCA collaborative study presented at ASH 2023.

Marcela Maus, MD, PhD, Associate Professor of Medicine at Harvard Medical School discussed innovative new research in the field and in her own lab.

A pooled analysis of the ALLCAR19 and FELIX trials including patients with R/R B-ALL, B-CLL, and B-NHL were presented at ASH 2023.

The hematologist and cell therapist from the University of Miami Sylvester Comprehensive Cancer Center spoke about long-term outcome data he presented at ASH’s 2023 conference.

The chief medical officer of Orca Bio discussed data the company presented on its Orca-T and Orca-Q programs at ASH 2023.

The associate professor at Peter MacCallum Cancer Centre discussed case study research from the center and possible contributions to the case.

The professor of hematology at University of Lille and chair of LYSA shared updated data from the TRANSCEND-FL trial.

The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed complete data from the PLAT-03 feasibility trial assessing SCRI-CAR19 and CD19t T-APCs in B-ALL.

A CRISPR/Cas9-edited allogeneic stem cell transplantation effectively reduced hematopoietic toxicity associated with maintenance gemtuzumab ozogamicin for high-risk acute myeloid leukemia (AML).

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed an analysis of female and male patient outcomes after axi-cel therapy.

Review top news and interview highlights from the week ending December 8, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The cell therapy yielded a median overall survival of around 17 months compared with a historical OS of less than 12 months.

ORR was 40% in the 10-mg group and 32% in the 100-mg group.

The assistant professor at MD Anderson Cancer Center discussed ongoing trials at MD Anderson and the TROP2 target for cell therapy.

Review top news and interview highlights from the week ending December 1, 2023.

Meanwhile, the company’s lead CAR Macrophage candidate CT-0508, continues to show efficacy in multiple solid tumor trials.

The Associate Professor of Medicine at Harvard Medical School discussed upcoming research and strategies to combat present hurdles in the treatment field.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company also plans to submit an MAA to the EMA in the first half of 2024.